Patrick DalyPNH | November 27, 2023
The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria.
Read More
Patrick DalyHematology | November 22, 2023
Tranexamic acid did not seem to increase risk of postoperative complications in patients undergoing total joint arthroplasty.
Patrick DalyHematology | November 21, 2023
The CHMP of the European Medicines Agency supported approving avapritinib for indolent systemic mastocytosis in Europe.
Patrick DalySickle Cell Disease | November 17, 2023
Markers of pulmonary impairment and inflammation were elevated in children with sickle cell disease and acute chest syndrome.
Patrick DalyHematology | November 16, 2023
Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis.
Patrick DalyAnemia | November 14, 2023
Testosterone replacement therapy improved anemia remission and new anemia prevention versus placebo in men with hypogonadism.
Patrick DalyDeep Vein Thrombosis | November 10, 2023
Asymptomatic DVT incidence was similar in patients with benign and malignant diseases prior to surgery for benign disease.
Patrick DalyVTE | November 8, 2023
Patients treated for isolated superficial vein thrombosis with anticoagulants still had a "substantial" risk of VTE later on.
Patrick DalyThrombosis | November 8, 2023
Splenomegaly and myeloproliferative disorders increased risk for porto-spleno-mesenteric venous thrombosis after splenectomy.
Patrick DalyAnemia | November 6, 2023
Fostamatinib improved hemoglobin response in warm antibody autoimmune hemolytic anemia versus placebo in the FORWARD trial.
Patrick DalySickle Cell Disease | November 2, 2023
A FDA Advisory Committee endorsed the safety of exa-cel, a genetic therapy with the potential to cure sickle cell disease.
Patrick DalyITP | October 31, 2023
Efgartigimod, a first-in-class IgG1 Fc fragment, promisingly separated from placebo in patients with chronic ITP.
Patrick DalyAnemia | October 30, 2023
Plasma thrombopoietin was significantly higher in aplastic anemia and myelodysplastic syndromes compared with control values.
Patrick DalyVTE | October 26, 2023
MPN-associated vascular thromboembolisms were more common in JAK2-mutated diseases and less common in CALR-mutated diseases.
Patrick DalyThrombosis | October 25, 2023
Edoxaban therapy for 12 months was superior to three-month therapy for preventing venous thromboembolisms and related deaths.
Patrick DalyAnemia | October 23, 2023
HSCT from a haploidentical donor and PTCy improved neutrophil and platelet engraftment compared with UCBT in aplastic anemia.
Patrick Dalyvon Willebrand Disease | October 20, 2023
Von Willebrand factor concentrate was not superior to tranexamic acid for reducing heavy menstrual bleeding in women.
Patrick DalyPNH | October 19, 2023
Iptacopan, a complement factor B inhibitor, was effective in patients with PNH with active hemolysis despite eculizumab use.
Patrick DalyHematology | October 16, 2023
Subclinical leaflet thrombosis appears more common after TAVR versus SAVR, but was not associated with increased stroke risk.
Patrick DalyPolycythemia Vera | October 16, 2023
Meta-analysis findings support the use of statins in patients with PV and ET to reduce mortality and thrombosis risk.
Latest News

December 1, 2023